JBS N.V. ( JBS) Q3 2025 Earnings Call November 14, 2025 9:00 AM EST Good morning, and welcome to JBS' Third Quarter of 2025 Results Conference Call. [Operator Instructions] As a reminder, this ...

DelveInsight's Antibody-mediated Rejection Market Insights report includes a comprehensive understanding of current treatment practices, antibody-mediated rejection emerging drugs, market share of ...

The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 ...

WRN inhibitors are attracting increasing attention as a niche but fast-emerging segment within precision oncology, driven by ...

The antibody-mediated rejection market is expanding as the number of organ transplants rises and awareness of AMR's impact on graft survival grows. Advances in diagnostic assays ...

WRN inhibitors are attracting increasing attention as a niche but fast-emerging segment within precision oncology, driven by their role in targeting DNA repair vulnerabilities.

The Madras High Court held that a taxpayer’s delay in withdrawing an appeal should not disqualify them from waiver of interest and penalty under Section 128A, where tax was fully paid before the ...